Advances in Treatment for Tumor-Induced Osteomalacia
Author Information
Author(s): Hartley Iris R., Roszko Kelly L.
Primary Institution: National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
Hypothesis
What are the effective treatment options for tumor-induced osteomalacia?
Conclusion
Recent innovations in medical and interventional treatments have improved options for patients with tumor-induced osteomalacia, especially when surgical resection is not possible.
Supporting Evidence
- Burosumab has been approved for treating tumor-induced osteomalacia and has shown improvements in phosphate levels and symptoms.
- Infigratinib can reverse biochemical abnormalities in tumor-induced osteomalacia but has serious side effects.
- Surgical resection remains the best definitive treatment for tumor-induced osteomalacia.
Takeaway
Tumor-induced osteomalacia is a rare condition that can make bones weak. New treatments can help people feel better and strengthen their bones, even if surgery isn't an option.
Methodology
The review discusses various treatment options including surgical resection, medical management with phosphate and calcitriol, and newer therapies like burosumab and infigratinib.
Limitations
The long-term efficacy of some treatments is still uncertain, and monitoring for tumor growth is necessary even with medical therapy.
Participant Demographics
The study involved adults with tumor-induced osteomalacia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website